Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence J Singerman

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Ophthalmology|October 8, 2018
Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical TrialEmily Y Chew, Traci E Clemons, Glenn J Jaffe, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|October 17, 2002
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5Mark S Blumenkranz, Neil M Bressler, Susan B Bressler, et al.
Ophthalmology|April 12, 2003
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3Kevin J Blinder, Mark S Blumenkranz, Neil M Bressler, et al.
Ophthalmology|September 3, 2019
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 TrialDavid S Liao, Federico V Grossi, Delphine El Mehdi, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Ophthalmology|October 8, 2018
Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical TrialEmily Y Chew, Traci E Clemons, Glenn J Jaffe, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|October 17, 2002
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5Mark S Blumenkranz, Neil M Bressler, Susan B Bressler, et al.
Ophthalmology|April 12, 2003
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3Kevin J Blinder, Mark S Blumenkranz, Neil M Bressler, et al.
Ophthalmology|September 3, 2019
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 TrialDavid S Liao, Federico V Grossi, Delphine El Mehdi, et al.
Pageof 3